Predictors of early hemorrhage in acute promyelocytic leukemia

References

• Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood. 2008;111:2505–2515.
   PubMed Web of Science ®Google Scholar
• Tallman MS, Andersen JW, Schiffer CA, et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood. 2002;100:4298–4302.
   PubMed Web of Science ®Google Scholar
• Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369:111–121.
   PubMed Web of Science ®Google Scholar
• Ades L, Guerci A, Raffoux E, et al. Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. Blood. 2010;115:1690–1696.
   PubMed Web of Science ®Google Scholar
• Sanz MA, Montesinos P, Rayon C, et al. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood. 2010;115:5137–5146.
   PubMed Web of Science ®Google Scholar
• Coombs CC, Tavakkoli M, Tallman MS. Acute promyelocytic leukemia: where did we start, where are we now, and the future. Blood Cancer J. 2015;5:e304.
   PubMed Web of Science ®Google Scholar
• Sanz MA, Lo Coco F, Martin G, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000;96:1247–1253.
   PubMed Web of Science ®Google Scholar
• Powell BL, Moser B, Stock W, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood. 2010;116:3751–3757.
   PubMed Web of Science ®Google Scholar
• de la Serna J, Montesinos P, Vellenga E, et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood. 2008;111:3395–3402.
   PubMed Web of Science ®Google Scholar
• Mantha S, Goldman DA, Devlin SM, et al. Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era. Blood. 2017;129:1763–1767.
   PubMed Web of Science ®Google Scholar
• Lehmann S, Ravn A, Carlsson L, et al. Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. Leukemia. 2011;25:1128–1134.
   PubMed Web of Science ®Google Scholar
• Tallman MS, Altman JK. How I treat acute promyelocytic leukemia. Blood. 2009;114:5126–5135.
   PubMed Web of Science ®Google Scholar
• Mitrovic M, Suvajdzic N, Bogdanovic A, et al. International Society of Thrombosis and Hemostasis Scoring System for disseminated intravascular coagulation >/= 6: a new predictor of hemorrhagic early death in acute promyelocytic leukemia. Med Oncol. 2013;30:478.
   PubMed Web of Science ®Google Scholar
• Song YH, Peng P, Qiao C, et al. Low platelet count is potentially the most important contributor to severe bleeding in patients newly diagnosed with acute promyelocytic leukemia. Ott. 2017;10:4917–4924.
   Google Scholar
• Yanada M, Matsushita T, Asou N, et al. Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome. Eur J Haematol. 2007;78:213–219.
   PubMed Web of Science ®Google Scholar
• Kim DY, Lee JH, Lee JH, et al. Significance of fibrinogen, D-dimer, and LDH levels in predicting the risk of bleeding in patients with acute promyelocytic leukemia. Leuk Res. 2011;35:152–158.
   PubMed Web of Science ®Google Scholar
• Chang H, Kuo MC, Shih LY, et al. Clinical bleeding events and laboratory coagulation profiles in acute promyelocytic leukemia. Eur J Haematol. 2012;88:321–328.
   PubMed Web of Science ®Google Scholar
• Breccia M, Latagliata R, Cannella L, et al. Early hemorrhagic death before starting therapy in acute promyelocytic leukemia: association with high WBC count, late diagnosis and delayed treatment initiation. Haematologica. 2010;95:853–854.
   PubMed Web of Science ®Google Scholar
• Dally N, Hoffman R, Haddad N, et al. Predictive factors of bleeding and thrombosis during induction therapy in acute promyelocytic leukemia-a single center experience in 34 patients. Thromb Res. 2005;116:109–114.
   PubMed Web of Science ®Google Scholar
• Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer. 1981;47:207–214.
   PubMed Web of Science ®Google Scholar
• Nagin DS. Group-based trajectory modeling: an overview. Ann Nutr Metab. 2014;65:205–210.
   PubMed Web of Science ®Google Scholar
• Nagin DS, Odgers CL. Group-based trajectory modeling in clinical research. Annu Rev Clin Psychol. 2010;6:109–138.
   PubMed Web of Science ®Google Scholar
• Choudhry A, DeLoughery TG. Bleeding and thrombosis in acute promyelocytic leukemia. Am J Hematol. 2012;87:596–603.
   PubMed Web of Science ®Google Scholar
• Mantha S, Tallman MS, Soff GA. What's new in the pathogenesis of the coagulopathy in acute promyelocytic leukemia? Curr Opin Hematol. 2016;23:121–126.
   PubMed Web of Science ®Google Scholar
• Menell JS, Cesarman GM, Jacovina AT, et al. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med. 1999;340:994–1004.
   PubMed Web of Science ®Google Scholar
• Montesinos P, Bergua JM, Vellenga E, et al. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood. 2009;113:775–783.
   PubMed Web of Science ®Google Scholar
• Sanz MA, Montesinos P. How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia. Blood. 2014;123:2777–2782.
   PubMed Web of Science ®Google Scholar
• Breen KA, Grimwade D, Hunt BJ. The pathogenesis and management of the coagulopathy of acute promyelocytic leukaemia. Br J Haematol. 2012;156:24–36.
   PubMed Web of Science ®Google Scholar
• Rodeghiero F, Avvisati G, Castaman G, et al. Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients. Blood. 1990;75:2112–2117.
   PubMed Web of Science ®Google Scholar